ANEB stock has a bullish outlook with a price target of $8, as reiterated by Benchmark analyst Robert Wasserman on November 19, 2024. The optimism stems from its progress in developing selonabant for cannabis toxicity and securing a $1.9 million grant to advance clinical trials. Despite financial challenges, the company's strategic focus and recent EPS beat (-$0.06 vs. -$0.12 estimate) support the positive sentiment.